Oral contraceptives and MS disease activity in a contemporary real-world cohort
There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course. To evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line inject...
Uloženo v:
| Vydáno v: | Multiple sclerosis Ročník 24; číslo 2; s. 227 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.02.2018
|
| Témata: | |
| ISSN: | 1477-0970, 1477-0970 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course.
To evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line injectable disease-modifying therapy (DMT).
From our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never. Our primary analysis was comparison of annualized relapse rate from baseline DMT start across the three OC use categories using a negative binomial regression model.
In this cohort of 162 women, 81 were treated with interferon therapy and 81 with glatiramer acetate. Mean ages for current-, past-, and never-OC users were 31.4 ( n = 46), 40.3 ( n = 66), and 37.9 ( n = 50) years, respectively ( p < 0.05); mean disease duration (1.0 years) and median baseline EDSS (1.0) did not differ between groups. Prior OC users had significantly lower relapse rates than never-users ( p = 0.031); the lower annualized relapse rate in current-users relative to never-users was not significant ( p = 0.91). Annualized relapse rate was not significantly different across the OC groups ( p = 0.057, three-group comparison).
These observations provide reassurance for women newly diagnosed that OC use, past or current, does not appear to be associated with greater risk of relapses. |
|---|---|
| AbstractList | There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course.
To evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line injectable disease-modifying therapy (DMT).
From our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never. Our primary analysis was comparison of annualized relapse rate from baseline DMT start across the three OC use categories using a negative binomial regression model.
In this cohort of 162 women, 81 were treated with interferon therapy and 81 with glatiramer acetate. Mean ages for current-, past-, and never-OC users were 31.4 ( n = 46), 40.3 ( n = 66), and 37.9 ( n = 50) years, respectively ( p < 0.05); mean disease duration (1.0 years) and median baseline EDSS (1.0) did not differ between groups. Prior OC users had significantly lower relapse rates than never-users ( p = 0.031); the lower annualized relapse rate in current-users relative to never-users was not significant ( p = 0.91). Annualized relapse rate was not significantly different across the OC groups ( p = 0.057, three-group comparison).
These observations provide reassurance for women newly diagnosed that OC use, past or current, does not appear to be associated with greater risk of relapses. There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course.BACKGROUNDThere is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course.To evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line injectable disease-modifying therapy (DMT).OBJECTIVETo evaluate the hypothesis that OC use is associated with decreased risk of relapses in an observational study of women of childbearing age with new-onset MS starting a first-line injectable disease-modifying therapy (DMT).From our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never. Our primary analysis was comparison of annualized relapse rate from baseline DMT start across the three OC use categories using a negative binomial regression model.METHODSFrom our CLIMB longitudinal observational study, we identified 162 women with MS or CIS with known OC use who initiated injectable DMT within two years of symptom onset, and categorized OC use at DMT onset as past, ever or never. Our primary analysis was comparison of annualized relapse rate from baseline DMT start across the three OC use categories using a negative binomial regression model.In this cohort of 162 women, 81 were treated with interferon therapy and 81 with glatiramer acetate. Mean ages for current-, past-, and never-OC users were 31.4 ( n = 46), 40.3 ( n = 66), and 37.9 ( n = 50) years, respectively ( p < 0.05); mean disease duration (1.0 years) and median baseline EDSS (1.0) did not differ between groups. Prior OC users had significantly lower relapse rates than never-users ( p = 0.031); the lower annualized relapse rate in current-users relative to never-users was not significant ( p = 0.91). Annualized relapse rate was not significantly different across the OC groups ( p = 0.057, three-group comparison).RESULTSIn this cohort of 162 women, 81 were treated with interferon therapy and 81 with glatiramer acetate. Mean ages for current-, past-, and never-OC users were 31.4 ( n = 46), 40.3 ( n = 66), and 37.9 ( n = 50) years, respectively ( p < 0.05); mean disease duration (1.0 years) and median baseline EDSS (1.0) did not differ between groups. Prior OC users had significantly lower relapse rates than never-users ( p = 0.031); the lower annualized relapse rate in current-users relative to never-users was not significant ( p = 0.91). Annualized relapse rate was not significantly different across the OC groups ( p = 0.057, three-group comparison).These observations provide reassurance for women newly diagnosed that OC use, past or current, does not appear to be associated with greater risk of relapses.RESULTSThese observations provide reassurance for women newly diagnosed that OC use, past or current, does not appear to be associated with greater risk of relapses. |
| Author | Rankin, Kelsey Greeke, Emily Stuart, Fiona Sattarnezhad, Neda Chitnis, Tanuja Saraceno, Taylor Glanz, Bonnie I LaRussa, Allison Bove, Riley Chua, Alicia S |
| Author_xml | – sequence: 1 givenname: Riley surname: Bove fullname: Bove, Riley organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA/Harvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Diseases, Harvard Medical School, Boston, MA, USA/Sandler Neurosciences Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA – sequence: 2 givenname: Kelsey surname: Rankin fullname: Rankin, Kelsey organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 3 givenname: Alicia S surname: Chua fullname: Chua, Alicia S organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 4 givenname: Taylor surname: Saraceno fullname: Saraceno, Taylor organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 5 givenname: Neda surname: Sattarnezhad fullname: Sattarnezhad, Neda organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 6 givenname: Emily surname: Greeke fullname: Greeke, Emily organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 7 givenname: Fiona surname: Stuart fullname: Stuart, Fiona organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 8 givenname: Allison surname: LaRussa fullname: LaRussa, Allison organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA – sequence: 9 givenname: Bonnie I surname: Glanz fullname: Glanz, Bonnie I organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Brookline, MA, USA/Harvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Diseases, Harvard Medical School, Boston, MA, USA – sequence: 10 givenname: Tanuja surname: Chitnis fullname: Chitnis, Tanuja organization: Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Brookline, MA, USA/Harvard Medical School, Boston, MA, USA/Ann Romney Center for Neurologic Diseases, Harvard Medical School, Boston, MA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28155573$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAYhIOsuB969yQ5eqnmTZMmOcriF6zsQT2XNHkXK21Tk1bZf2_RFTzNMDwMwyzJrAsdEnIO7ApAqWvIJRdSS1CF4YKzI7IAoVTGjGKzf35Olim9M8aUyuUJmXMNUkqVL8h2G21DXeiGaB32Q_2JidrO06dn6uuENiG1borrYU_rjtofFts-RBv3NKJtsq8QGz_lbyEOp-R4Z5uEZwddkde725f1Q7bZ3j-ubzaZE7kcMpc7wZzxUJhCCJwUhQAjmdWVE5XBAqyWlawKVxhwQnuzMxZYZZwHxRxfkcvf3j6GjxHTULZ1ctg0tsMwphJ0ISXnoPmEXhzQsWrRl32s22l7-XcC_wbb1WAr |
| CitedBy_id | crossref_primary_10_3390_biomedicines7020032 crossref_primary_10_3389_fneur_2019_00060 crossref_primary_10_3389_fneur_2022_1035596 crossref_primary_10_1016_j_msard_2021_102881 crossref_primary_10_1007_s11910_023_01326_7 crossref_primary_10_4103_jfcm_jfcm_263_24 crossref_primary_10_1038_s41582_024_01042_x crossref_primary_10_1177_13524585211053001 crossref_primary_10_3390_jcm13020464 crossref_primary_10_1111_ene_15299 crossref_primary_10_1016_j_yfrne_2020_100889 crossref_primary_10_1080_14656566_2020_1774554 crossref_primary_10_1111_jon_12709 crossref_primary_10_1212_WNL_0000000000208059 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1177/1352458517692420 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-0970 |
| ExternalDocumentID | 28155573 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GroupedDBID | --- -TM .2E .2F .2G .2J .2N 01A 0R~ 123 18M 1~K 29M 31R 31S 31U 31X 31Y 31Z 36B 39C 4.4 53G 54M 5VS 7X7 88E 8FI 8FJ 8R4 8R5 AABMB AABOD AACKU AACMV AACTG AADUE AAEJI AAEWN AAGGD AAGLT AAGMC AAJIQ AAJOX AAJPV AAKGS AANSI AAPEO AAPII AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAXOT AAYTG AAZBJ ABAFQ ABAWC ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHFT ABHKI ABHQH ABIDT ABJIS ABJNI ABJZC ABKRH ABLUO ABNCE ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACNXM ACOFE ACOXC ACPRK ACROE ACRPL ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEBD ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADSTG ADTBJ ADUCT ADUKL ADVBO ADYCS ADZYD ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFUIA AFVCE AFWMB AGHKR AGKLV AGNHF AGPXR AGQPQ AGWFA AGWNL AHDMH AHHFK AHMBA AIGRN AJABX AJEFB AJGYC AJMMQ AJSCY AJUZI AJVBE AJXAJ AJXGE ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS AMCVQ ANDLU ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN AZQEC B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BENPR BKIIM BKNYI BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD BYIEH CAG CBRKF CCPQU CDWPY CFDXU COF CORYS CQQTX CS3 CUTAK DB0 DC- DC0 DD- DD0 DE- DF0 DO- DOPDO DU5 DV7 DV9 D~Y EBS EJD EMOBN F5P FD6 FEDTE FHBDP FYUFA GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HMCUK HVGLF HZ~ J8X K.F K.J K9- M0R M1P N9A NPM O9- P.B P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO Q1R Q2X Q7K Q7L Q7R Q7U Q7X Q82 Q83 ROL S01 SASJQ SAUOL SCNPE SDB SFB SFC SFK SFN SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPQ SPV SQCSI STM UKHRP XJT ZONMY ZPPRI ZRKOI ZSSAH 7X8 AJHME |
| ID | FETCH-LOGICAL-c435t-c3c40c9d169644ed16e441950a8bc4b9e61a85b5b6c691c48d9f9a10b9cd170c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000429033400100&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-0970 |
| IngestDate | Sun Sep 28 04:39:52 EDT 2025 Mon Jul 21 05:53:00 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Hormone estrogen pill multiple sclerosis oral contraceptive |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c435t-c3c40c9d169644ed16e441950a8bc4b9e61a85b5b6c691c48d9f9a10b9cd170c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 28155573 |
| PQID | 1865522182 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1865522182 pubmed_primary_28155573 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-01 |
| PublicationDateYYYYMMDD | 2018-02-01 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Multiple sclerosis |
| PublicationTitleAlternate | Mult Scler |
| PublicationYear | 2018 |
| SSID | ssj0007735 |
| Score | 2.3029501 |
| Snippet | There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course.
To evaluate the hypothesis that OC use is... There is uncertainty regarding the effect of oral hormonal contraceptives (OC) on multiple sclerosis (MS) course.BACKGROUNDThere is uncertainty regarding the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 227 |
| Title | Oral contraceptives and MS disease activity in a contemporary real-world cohort |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28155573 https://www.proquest.com/docview/1865522182 |
| Volume | 24 |
| WOSCitedRecordID | wos000429033400100&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3JS8QwFMaDOiJe3JdxI4LXME2bpTmJiIOXWUCFuZVshQHpjNNx_n5f0g5zEgQv7aEtlOQ1_SXfy_sQejAZ1xQ4nnDuGWHKOaK99kR5xsqSeceZjmYTcjjMJxM1bhfc6jatcj0mxoHazWxYI-_RsIMyDfXGH-dfJLhGBXW1tdDYRp0MUCZEtZxsqoVLGQ02KZOSJEomG5myRwE8WJDEpIAZSJr8DpjxR9M__O8rHqGDFjHxUxMTx2jLVydob9CK6KdoNFrA5ZijrmNSy8rXWFcOD95wq9fgsN0huErgaYV1vHddwgoDZX6SWGgVB3fdxfIMffRf3p9fSeurQCzA0ZLYzLLEKkeFAhrycIaOCXawOjeWGeUF1Tk33AgrFLUsd6pUmiZGWUdlYtNztFPNKn-JsOHSAyEIA1QCE8tMl8YAMOhMlF5kxnbR_bqpCojbIEboys--62LTWF100bR3MW8KbBRpDpTDZXb1h6ev0T4wTN4kUt-gTglfrb9Fu3a1nNaLuxgQcByOBz8Crb_T |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oral+contraceptives+and+MS+disease+activity+in+a+contemporary+real-world+cohort&rft.jtitle=Multiple+sclerosis&rft.au=Bove%2C+Riley&rft.au=Rankin%2C+Kelsey&rft.au=Chua%2C+Alicia+S&rft.au=Saraceno%2C+Taylor&rft.date=2018-02-01&rft.eissn=1477-0970&rft.volume=24&rft.issue=2&rft.spage=227&rft_id=info:doi/10.1177%2F1352458517692420&rft_id=info%3Apmid%2F28155573&rft_id=info%3Apmid%2F28155573&rft.externalDocID=28155573 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-0970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-0970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-0970&client=summon |